Skip to main content
. 2024 Feb 12;14:1258991. doi: 10.3389/fonc.2024.1258991

Table 3.

Two-year cumulative incidence of cardiac adverse events in patients with primary NSCLC cancer treated with crizotinib (49).

Cardiac Adverse Event Population Cumulative incidence rates (95% CI), %
Bradycardia EU 1.1 (0.0-3.0)
USA 16.9 (10.5-24.7)
QT interval prolongation related events EU 1.0 (0.0-3.1)
USA 26.8 (17.6 - 36.9)
Cardiac failure EU 0.5 (0.0 – 2.1)
USA 6.8 (3.4 – 11.7)